ACELOT, INC.
Drug-like LXRβ selective agonist molecules for Alzheimer's disease, discovered via machine learning-enabled pharmacophore prediction and biological screening
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2021
- Latest Form D
- $4M, Nov 2024
- Total capital
- $4.2M
- Federal grants
- $223K
- 1 award · 2016
- Rank in peer group#331 of 392
- Private capital raised
- $4M
- 1 Form D · last Nov 2024
- 23 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 17 pending · first 2020
- Rank in peer group#40 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4M
- Federal grantHealth and Human S · Phase I · Discovery of LXR Agonists via Pharmacophore Space Mining$223K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
98months
from ACELOT, INC.’s first federal award to its first private round.
- First federal award · Sep 2016
- Health and Human S · $223K
- First Form D · Nov 2024
- $4M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#40 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ambuj SinghResearcherDirectorLinked by 3 patents
- Catherine PlaneyExecutive Officer, DirectorNamed in SEC Form D filings
- Ed O'SullivanExecutive OfficerNamed in SEC Form D filings
- Michael DucaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 20- PendingSmall Molecule Drugs And Related Methods For Treatment Of Diseases Related To TDP-43, Alpha-synuclein, Huntingtin's Protein And Tau Protein Oligomer FormationUSPTOApplication 19196507
- PendingSmall Molecule Drugs And Related Methods For Treatment Of Diseases Related To AB42 Oligomer FormationUSPTOApplication 19183551
- GrantedSubstituted Piperazines As Disrupters Of AB42 Oligomer FormationUSPTOUS 12,312,296
Show all 20 patent records
- Small Molecule Drugs And Related Methods For Treatment Of Diseases Related To TDP-43, Alpha-synuclein, Huntingtin's Protein And Tau Protein Oligomer FormationJul 2, 2026 · Application 19196507Pending
- Small Molecule Drugs And Related Methods For Treatment Of Diseases Related To AB42 Oligomer FormationJun 25, 2026 · Application 19183551Pending
- Substituted Piperazines As Disrupters Of AB42 Oligomer FormationMay 27, 2025 · US 12,312,296Granted
- Substituted Amines As Disrupters Of ABETA42 Oligomer FormationNov 28, 2023 · US 11,827,582Granted
- Small Molecule Drugs And Related Methods For Treatment Of Diseases Related To ABETA42 Oligomer FormationJul 7, 2020 · US 10,703,711Granted
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63737165Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63706158Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication PCTUS2024024489Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication PCTUS2024024481Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63612107Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63459198Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63459196Pending
- Small Molecule Drugs And Related Methods For Treatment Of Diseases Related To TDP-43, Alpha-synuclein, Huntingtin's Protein And Tau Protein Oligomer FormationApplication PCTUS2020000030Pending
- Small Molecule Drugs And Related Methods For Treatment Of Diseases Related To ABE42 Oligomer FormationApplication PCTUS2018000386Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication PCTUS2025060329Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 19472025Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication PCTUS2025050095Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 19472024Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63737161Pending
- Compounds And Methods For Treating Protein Aggregation DiseasesApplication 63737167Pending
Related companies, and why
- NiKang TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Praeventix, LLCSimilar federal contract value in Biotech · null in contracts
- ABILITA BIO, INC.Similar federal contract value in Biotech · null in contracts
- DeuteRx LLCSimilar federal contract value in Biotech · null in contracts
- FGH BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
- RegulonixSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .